HONG KONG SAR – Media OutReach Newswire – March 27, 2024 –
AIM Vaccine Co., Ltd. (the “AIM Vaccine”, with its subsidiaries, the group”) is pleased to announce that the Group submitted on March 24, 2024 the pre-application for clinical trials for a new highly effective human diploid vaccine against human rabies.
Currently, there is a lack of effective clinical treatment for rabies and post-exposure prevention is therefore crucial. The main preventive measures are inoculation of human rabies vaccine and injection of passive immunization agents. Human diploid cell rabies vaccine has natural safety advantages and broad market space. This time, AIM Vaccine submitted a pre-application for clinical trials for a new highly effective human diploid vaccine against diploid rabies, which is a major breakthrough.
The new highly effective human diploid rabies vaccine developed by AIM Vaccine has become the first to overcome the technical bottleneck of low viral titer and low yield of the traditional process, with an optimized and innovative purification process, which has significantly improved product quality and safety compared with similar products marketed in China and has the production capacity for large-scale marketing.
Hashtag: #VaccinAIM
The issuer is solely responsible for the content of this announcement.
